NASDAQ:NCNA

NuCana Competitors

$4.09
+0.06 (+1.49 %)
(As of 04/21/2021 10:27 AM ET)
Add
Compare
Today's Range
$4.00
Now: $4.09
$4.09
50-Day Range
$4.17
MA: $4.95
$5.70
52-Week Range
$3.95
Now: $4.09
$7.83
Volume218 shs
Average Volume497,198 shs
Market Capitalization$198.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.92

Competitors

NuCana (NASDAQ:NCNA) Vs. ESPR, ORIC, HGEN, KPTI, LXRX, and ICPT

Should you be buying NCNA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to NuCana, including Esperion Therapeutics (ESPR), ORIC Pharmaceuticals (ORIC), Humanigen (HGEN), Karyopharm Therapeutics (KPTI), Lexicon Pharmaceuticals (LXRX), and Intercept Pharmaceuticals (ICPT).

NuCana (NASDAQ:NCNA) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings & Valuation

This table compares NuCana and Esperion Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A$-27,340,000.00($0.84)-4.87
Esperion Therapeutics$148.36 million5.15$-97,170,000.00($3.59)-7.56

NuCana has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NuCana and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuCanaN/A-35.90%-32.56%
Esperion Therapeutics-46.15%-629.88%-41.43%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NuCana and Esperion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuCana01502.83
Esperion Therapeutics24312.30

NuCana presently has a consensus price target of $17.50, indicating a potential upside of 327.87%. Esperion Therapeutics has a consensus price target of $50.60, indicating a potential upside of 86.44%. Given NuCana's stronger consensus rating and higher possible upside, analysts plainly believe NuCana is more favorable than Esperion Therapeutics.

Institutional & Insider Ownership

84.1% of NuCana shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

NuCana has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Summary

NuCana beats Esperion Therapeutics on 10 of the 14 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares ORIC Pharmaceuticals and NuCana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
NuCanaN/A-35.90%-32.56%

Analyst Recommendations

This is a breakdown of current ratings for ORIC Pharmaceuticals and NuCana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
NuCana01502.83

ORIC Pharmaceuticals presently has a consensus target price of $43.7143, indicating a potential upside of 107.57%. NuCana has a consensus target price of $17.50, indicating a potential upside of 327.87%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than ORIC Pharmaceuticals.

Valuation and Earnings

This table compares ORIC Pharmaceuticals and NuCana's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
NuCanaN/AN/A$-27,340,000.00($0.84)-4.87

Institutional & Insider Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 84.1% of NuCana shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ORIC Pharmaceuticals beats NuCana on 4 of the 6 factors compared between the two stocks.

Humanigen (NASDAQ:HGEN) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

30.2% of Humanigen shares are held by institutional investors. Comparatively, 84.1% of NuCana shares are held by institutional investors. 37.5% of Humanigen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Humanigen and NuCana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
NuCanaN/A-35.90%-32.56%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Humanigen and NuCana, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
NuCana01502.83

Humanigen presently has a consensus target price of $29.8333, indicating a potential upside of 106.03%. NuCana has a consensus target price of $17.50, indicating a potential upside of 327.87%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than Humanigen.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its stock price is 179% less volatile than the S&P 500. Comparatively, NuCana has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Earnings & Valuation

This table compares Humanigen and NuCana's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
NuCanaN/AN/A$-27,340,000.00($0.84)-4.87

Summary

NuCana beats Humanigen on 5 of the 7 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.

Earnings & Valuation

This table compares Karyopharm Therapeutics and NuCana's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million17.42$-199,590,000.00($3.22)-2.95
NuCanaN/AN/A$-27,340,000.00($0.84)-4.87

NuCana has lower revenue, but higher earnings than Karyopharm Therapeutics. NuCana is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Karyopharm Therapeutics and NuCana, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
NuCana01502.83

Karyopharm Therapeutics presently has a consensus target price of $29.8750, indicating a potential upside of 214.81%. NuCana has a consensus target price of $17.50, indicating a potential upside of 327.87%. Given NuCana's higher possible upside, analysts clearly believe NuCana is more favorable than Karyopharm Therapeutics.

Profitability

This table compares Karyopharm Therapeutics and NuCana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
NuCanaN/A-35.90%-32.56%

Institutional and Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 84.1% of NuCana shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Karyopharm Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, NuCana has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Karyopharm Therapeutics beats NuCana on 7 of the 13 factors compared between the two stocks.

NuCana (NASDAQ:NCNA) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

This table compares NuCana and Lexicon Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A$-27,340,000.00($0.84)-4.87
Lexicon Pharmaceuticals$322.07 million2.25$130.13 million$1.353.72

Lexicon Pharmaceuticals has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for NuCana and Lexicon Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuCana01502.83
Lexicon Pharmaceuticals06202.25

NuCana currently has a consensus target price of $17.50, indicating a potential upside of 327.87%. Lexicon Pharmaceuticals has a consensus target price of $9.40, indicating a potential upside of 87.25%. Given NuCana's stronger consensus rating and higher possible upside, equities analysts plainly believe NuCana is more favorable than Lexicon Pharmaceuticals.

Profitability

This table compares NuCana and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuCanaN/A-35.90%-32.56%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Institutional & Insider Ownership

84.1% of NuCana shares are held by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

NuCana has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500.

Summary

Lexicon Pharmaceuticals beats NuCana on 7 of the 13 factors compared between the two stocks.

NuCana (NASDAQ:NCNA) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

This table compares NuCana and Intercept Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuCanaN/AN/A$-27,340,000.00($0.84)-4.87
Intercept Pharmaceuticals$252 million2.74$-344,680,000.00($10.89)-1.91

NuCana has higher earnings, but lower revenue than Intercept Pharmaceuticals. NuCana is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for NuCana and Intercept Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuCana01502.83
Intercept Pharmaceuticals115802.29

NuCana currently has a consensus target price of $17.50, indicating a potential upside of 327.87%. Intercept Pharmaceuticals has a consensus target price of $50.6957, indicating a potential upside of 145.74%. Given NuCana's stronger consensus rating and higher possible upside, equities analysts plainly believe NuCana is more favorable than Intercept Pharmaceuticals.

Profitability

This table compares NuCana and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuCanaN/A-35.90%-32.56%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Institutional & Insider Ownership

84.1% of NuCana shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

NuCana has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Summary

NuCana beats Intercept Pharmaceuticals on 7 of the 13 factors compared between the two stocks.


NuCana Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.14+1.5%$775.42 million$148.36 million-7.05
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.06+0.2%$771.33 millionN/A0.00Increase in Short Interest
Humanigen logo
HGEN
Humanigen
1.7$14.44+6.2%$724.15 millionN/A0.00Analyst Report
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.49+0.5%$708.58 million$40.89 million-3.27
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.02+2.8%$704.45 million$322.07 million-4.78Upcoming Earnings
Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.85+0.2%$689.77 million$252 million-2.13
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.18+0.3%$682.20 million$150,000.00-4.54News Coverage
Chimerix logo
CMRX
Chimerix
1.3$8.04+1.6%$677.72 million$12.52 million-14.11Gap Up
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.85+1.8%$677.00 million$13.80 million-14.42Analyst Report
News Coverage
Gap Up
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.22+1.8%$664.26 million$6.83 million-18.78
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.74+4.7%$662.95 million$2.22 million-16.12News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.86+0.8%$658.06 million$5.09 million-6.43
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.98+3.6%$649.75 million$19.56 million-19.41Gap Down
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$14.40+6.8%$647.33 million$1.52 million-7.66Analyst Report
Unusual Options Activity
News Coverage
Veru logo
VERU
Veru
1.4$9.13+2.7%$638.58 million$42.59 million-32.61Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.02+2.3%$621.67 million$17.26 million-4.17Analyst Revision
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.28+1.0%$619.33 millionN/A-2.33Increase in Short Interest
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.54+0.3%$603.93 million$59.29 million-23.60Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.49+0.1%$602.28 million$9.64 million-5.13
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.96+0.2%$599.59 million$8 million-8.10
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.01+2.4%$598.75 millionN/A-10.11Analyst Report
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.89+3.7%$592.69 million$143.01 million-1.12
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.59+0.3%$581.37 million$26.74 million18.98
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.50+0.5%$580.62 millionN/A-15.97
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.34+4.4%$578.15 millionN/A-4.55Analyst Upgrade
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.05+1.8%$573.91 million$12.69 million-11.56News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.0$42.77+0.2%$566.61 million$195.89 million122.20
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.20+3.8%$546.63 million$1.19 million-7.17Gap Down
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.10+1.3%$543.69 millionN/A-5.26Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$2.47+5.3%$543.51 million$64.61 million-3.63Analyst Report
Decrease in Short Interest
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.97+2.2%$526.59 millionN/A-4.74
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.58+4.8%$523.94 millionN/A-8.98
89bio logo
ETNB
89bio
1.6$27.57+6.4%$517.10 millionN/A-5.46Analyst Report
Insider Selling
Gap Down
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$8.19+2.8%$515.68 million$57.49 million-6.88Gap Up
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.02+3.7%$515.18 millionN/A-5.65Analyst Upgrade
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.14+2.4%$513.23 millionN/A-8.32
Inventiva logo
IVA
Inventiva
0.0$13.27+0.9%$512.62 millionN/A0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.95+0.8%$509.61 million$25 million-18.38News Coverage
Gap Up
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.16+2.2%$507.37 millionN/A-4.08
Akouos logo
AKUS
Akouos
1.6$14.09+3.6%$502.27 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$7.78+0.4%$494.96 millionN/A-5.22Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$16.64+1.0%$485.48 millionN/A1.15News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50+1.9%$484.34 million$58.12 million-15.70
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.35+2.0%$478.24 million$59.22 million41.75
AC Immune logo
ACIU
AC Immune
1.3$6.75+3.6%$468.31 million$111.75 million-7.50Analyst Upgrade
Analyst Revision
News Coverage
Verastem logo
VSTM
Verastem
1.1$2.78+2.5%$465.22 million$17.46 million-1.97
Evolus logo
EOLS
Evolus
1.3$11.69+9.8%$461.38 million$34.92 million-5.76
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.16+1.3%$460.03 million$49.65 million-1.63
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.41+0.5%$455.79 million$102.31 million6.58Increase in Short Interest
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.